QIAGEN offers testing solutions to help combat avian flu outbreak threatening poultry across Europe and Asia Pacific
Dec 18 2014

QIAGEN offers testing solutions to help combat avian flu outbreak threatening poultry across Europe and Asia Pacific

  • QIAGEN’s ready-to-use virotype® Influenza A RT-PCR Kit detects a broad range of Influenza A virus subtypes including highly pathogenic H5N8 within two hours
  • Veterinary testing portfolio from QIAGEN includes complete test kits for Influenza A virus in poultry and swine, sample technologies, reagents and instruments
  • Poultry industry fights severe losses from avian flu, including more than 12 million animals lost in the current H5N8 outbreak

HILDEN and LEIPZIG, Germany, December 18, 2014 – QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today announced it is providing a broad range of advanced testing solutions for veterinary laboratories and agencies to combat influenza A in poultry amid a serious outbreak on the rise in Europe and Asia Pacific. The spread of highly pathogenic H5N8 strain of avian influenza A has caused severe losses to the poultry industry, including deaths of more than 12 million animals so far. QIAGEN’s portfolio to enable rapid detection includes the highly reliable, ready-to-use virotype Influenza A RT-PCR Kit developed by QIAGEN’s Center of Excellence for Veterinary Diagnostics in Leipzig, Germany, as well as a broad line of instruments and consumables enabling complete workflows - from sample to insight. The virotype Influenza A assay kit enables detection within just two hours of the RNA for the 16 HA and nine NA subtypes of the virus in poultry and swine samples, including the highly pathogenic H5N8 subtype. The virotype Influenza A kit runs on QIAGEN’s detection platform Rotor-Gene® Q, a member of the QIAsymphony® instruments family.

“We are working with veterinary agencies and laboratories on the front lines by providing diagnostic tools - from sample to insight - for the fight against avian influenza A in Europe and Asia Pacific. Our rapid-detection virotype Influenza A RT-PCR assay can help stop the epidemic before it causes more animal deaths and financial damage to the poultry industry,” said Dr. Carsten Schroeder, QIAGEN’s Director of Market Development, Veterinary Applications. “As a trusted partner for vet labs, animal health agencies and the industry, QIAGEN is supplying novel, highly reliable molecular testing solutions, allowing identification in just two hours of this deadly pathogen that can devastate poultry flocks if it spreads.”

Since the beginning of the 2014 outbreak of Influenza A (H5N8), tens of thousands of samples have been prepared and analyzed using QIAGEN sample technologies, reagents and test kits – and on QIAGEN instrumentation solutions. QIAGEN’s virotype Influenza A RT-PCR Kit is the only real-time reverse transcription polymerase chain reaction test approved for use in Germany by the Friedrich-Loeffler-Institut (FLI), Germany’s Federal Research Institute for Animal Health, for direct detection of Influenza A RNA including the highly pathogenic H5N8 virus. The ready-to-use virotype test kit contains all the reagents necessary to detect the viral RNA and can be used for high-throughput testing. (For up-to-date licensing information and product-specific disclaimers, see the respective kit handbook or user manual available at www.qiagen.com. Not validated for diagnosis of disease in animals – for research purposes only – in the United States, Japan and Canada.)

Concerns about avian flu spreading

Authorities such as the UN’s Food and Agriculture Organization (FAO) and the World Organisation for Animal Health (OIE) are warning about the rapid spread of the pathogenic H5N8 avian flu, which struck poultry farms in China, Japan and South Korea earlier in 2014. In November, outbreaks of H5N8 caused thousands of animal deaths on poultry farms in Germany, the United Kingdom, the Netherlands and India. The infection has also been found in migratory birds, which can spread avian flu to domestic flocks. The influenza A H5N8 virus has not yet been detected among humans and transmission to humans is believed to be very unlikely.

Veterinary labs and agencies are stepping up surveillance and detection efforts, as well as biosecurity measures such as minimizing contact between domestic poultry and wild birds. Among the agencies using QIAGEN solutions in the avian flu outbreak is the UK Government’s Animal and Plant Health Agency (APHA), successor to the Animal Health and Veterinary Laboratories Agency (AHVLA). APHA serves as an avian influenza reference laboratory for the European Union and the World Organisation for Animal Health (OIE) and is also the UK national reference laboratory for avian influenza.

QIAGEN Animal & Veterinary Testing: Excellence in animal health

QIAGEN supplies high-quality solutions for molecular biological and serological testing, as well as research into animal pathogens, from sample prep to results. QIAGEN’s products for veterinary medicine and disease investigation include a wide range of pathogen-specific PCR assays, ELISA kits and high-quality test systems for detection of diseases such as bluetongue disease and swine fever. QIAGEN Leipzig is the company’s center of excellence for veterinary diagnostics. As part of QIAGEN’s Applied Testing group, animal health activities such as veterinary R&D, market development, marketing, sales and test kit production are concentrated in Leipzig.

For more information, visit www.qiagen.com/animal-health.


QIAGEN N.V., a Netherlands-based holding company, is the leading global provider of Sample & Assay Technologies that are used to transform biological materials into valuable molecular information. Sample technologies are used to isolate and process DNA, RNA and proteins from biological samples such as blood or tissue. Assay technologies are then used to make these isolated biomolecules visible and ready for interpretation. QIAGEN markets more than 500 products around the world, selling both consumable kits and automation systems to customers through four customer classes: Molecular Diagnostics (human healthcare), Applied Testing (forensics, veterinary testing and food safety), Pharma (pharmaceutical and biotechnology companies) and Academia (life sciences research). As of September 30, 2014, QIAGEN employed approximately 4,200 people in over 35 locations worldwide. Further information can be found at http://www.qiagen.com.

Certain of the statements contained in this news release may be considered forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. To the extent that any of the statements contained herein relating to QIAGEN's products, markets, strategy or operating results, including without limitation its expected operating results, are forward-looking, such statements are based on current expectations and assumptions that involve a number of uncertainties and risks. Such uncertainties and risks include, but are not limited to, risks associated with management of growth and international operations (including the effects of currency fluctuations, regulatory processes and dependence on logistics), variability of operating results and allocations between customer classes, the commercial development of markets for our products in applied testing, personalized healthcare, clinical research, proteomics, women's health/HPV testing and nucleic acid-based molecular diagnostics; changing relationships with customers, suppliers and strategic partners; competition; rapid or unexpected changes in technologies; fluctuations in demand for QIAGEN's products (including fluctuations due to general economic conditions, the level and timing of customers' funding, budgets and other factors); our ability to obtain regulatory approval of our products; difficulties in successfully adapting QIAGEN's products to integrated solutions and producing such products; the ability of QIAGEN to identify and develop new products and to differentiate and protect our products from competitors' products; market acceptance of QIAGEN's new products, the consummation of acquisitions, and the integration of acquired technologies and businesses. For further information, please refer to the discussions in reports that QIAGEN has filed with, or furnished to, the U.S. Securities and Exchange Commission (SEC).


Share this page